Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial

作者：Edward A. Weinstein, Roger Paredes, Annie Gardner, Mary Almas, Mary Lynn Baniecki, Shunjie Guan, Elena Tudone, Simone Antonucci, Kevin Gregg, Carolina García‐Vidal, Adrián Camacho-Ortíz, Wayne Wisemandle, Steven G. Terra, Sean Liu, Judith A. Aberg, Meenakshi Rana, Lawrence Corey, Emily S. Ford, Jennifer Hammond, James M. Rusnak · 发表于：The Lancet Infectious Diseases · 年份：2025 · DOI：10.1016/s1473-3099(25)00221-x · 被引用次数：23 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Long-Term Effects of COVID-19